“3.1 The Employee agrees with the Company, that they will not, for a period of 12 months after the termination of their employment with the Company for whatever reason, be involved directly or indirectly, in any activity, whether as a self-employed person or as an employee, even on an occasional basis or without remuneration as a partner, director, employee, contractor, assistant, or agent, independently of their duties under their new business relationship for the benefit of any-subject, natural or legal person, company or other entity howsoever defined that carries out any business activity that would compete with the business activity as carried out by the Company or any of its affiliates, including each entity in the Group (together, the “Group Companies”), or that any Group Company was actively considering carrying out as evidenced by board minutes, at the date of termination of the Employee’s employment, including collection of bile or other related animal products, processing of bile or other related animal products, conversion of bile or other related animal products for pharmaceutical use, any activities relating to the supply chain, manufacturing or use of bile from various animals, including but not limited to cattle, chicken, pigs; any business related to cholic acid or any derivatives (including UDCA – ursodeoxycholic acid), and anything that is either related to or is a substitute of [sic] such products; any pharmaceutical business that involves applications for gallstone dissolution, PBC (primary biliary cholangitis), or other liver or GI (gastrointestinal) related conditions. For the purposes of this non-compete covenant, amongst the companies which are to be considered as competitors, are included by way of example, the following (including the relevant parent subsidiaries and/or affiliates): Belling, Pharmazell, Dipharma. Falk/Tiefenbacher, Pro.Med, Riverson, Cheplapharm, Daewoong Mitsubishi Pharma.”
“3.2 The Employee covenants and agrees that the Employee will not following the termination of the Employee’s employment (however terminated) for a period of 12 months, without the prior written consent of the Company, do any of the following: a. directly or indirectly induce or solicit or endeavour to induce or solicit, any person who or entity which was at any time within the 12 month period prior to the termination of the Employee’s employment, was a client or customer of any Group Company and with whom the Employee had direct dealings during the 12 months prior to the termination of the Employee’s employment, to cease doing business with the relevant Group Company or to reduce the amount of business which the person or entity would normally do with the relevant Group Company; b. directly or indirectly approach, entice away or deal in trade with any person who or entity which, within the 12 month period prior to the termination of the Employee’s employment, was a client or customer of any Group Company and with whom the Employee has direct dealings during the 12 months prior to the termination of the Employee’s employment; and 3.3 The obligations set out under the above covenants will be valid within the territory of the United Kingdom. Considering the current technological resources (including, but not limited to, email and video conferencing), allowing a dissociation between the place in which the activity may be carried out and the place in which it may be used and, in any event, take effect, the restriction referred to above shall be deemed to relate to both places and shall therefore be binding not just with regard to the place in which the activity is carried out, in any form, but also the place in which such activity is intended to take direct effect, permanently and regularly, irrespective of the physical presence of the Employee in that place. 3.4 In consideration of the obligations set out above, the Company will pay the Employee a gross amount equal to 100% of the last annual gross salary, calculated on the basis of (i) the annual gross base salary applicable at the date of termination of the Employment; (ii) the average of the cash bonuses paid by the Company to the Employee during the 3 years preceding the date of termination of the Employment, and of any potential stock option/stock grants or the like potentially assigned to the Employee; and (i) the value indicated under the relevant payslip of the benefits potentially assigned to the Employee as at the date of termination of the Employment. This amount will be paid by the Company to the Employee after the termination of the Employment, during the period of effectiveness of the non-compete, in quarterly consecutive equal instalments and any of these instalments will be due on the last day of each quarter, on the proviso that the Employee fulfils the non- compete obligations. 3.5 The Employee and the Company agree that the obligations set in this variation are reasonable and that the consideration above is reasonable and that they intend the obligations in this clause to operate to the maximum extent. 3.6 In the event of any conflict between the provisions of this clause 3 and any other arrangement, the provisions of this Agreement shall prevail, unless the relevant clause of the relevant arrangement expressly provides that it shall prevail, thereby referencing the clause of this Agreement over which the applicable schedule is intended to prevail.”
“There are some areas of factual dispute to be resolved at trial as necessary, but my starting point for the purposes of the application before me is the facts as asserted in Dr Viney's statements for the claimants, though Ms Stone says that where there are material disputes of fact this may have a bearing on whether I should grant interim relief until such disputes can be resolved as the result of a trial.”